MEOBF MESOBLAST LTD
Price Chart
Executive Summary
Mesoblast hosted an R&D Day event highlighting commercial progress of its FDA-approved product Ryoncil and upcoming milestones for its late-stage clinical pipeline. The company reported net revenue approaching $100M since Ryoncil's launch and announced key trial timelines for its chronic back pain and heart failure programs.
Actionable Insight
The company's strong cash position and revenue generation from Ryoncil provide runway for its clinical programs. The upcoming milestones in adult SR-aGvHD and CLBP could be significant value drivers. Investors should monitor progress in these trials and potential regulatory interactions.
Key Facts
- Ryoncil net revenue approaching $100M since launch
- Adult SR-aGvHD Phase 3 trial initiated with BMT-CTN network
- FDA cleared IND for Ryoncil in Duchenne Muscular Dystrophy
- Enrollment completion expected for CLBP Phase 3 trial by end of April 2026
- Top-line results expected mid-2027 for CLBP trial
- Cash balance of $130M at December 31, 2025
- New term loan of $125M replaces existing higher-cost debt
Financial Impact
Net revenue approaching $100M since launch; $130M cash balance; $125M new term loan
Risk Factors
- Clinical trial failures in adult SR-aGvHD or CLBP programs
- Regulatory delays in approval pathways
- Competition in the allogeneic cell therapy space
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000045 |
| Exhibit: exhibit991rddaypresentat.htm | 0001345099-26-000045 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000045 |
| Document: 0001345099-26-000045-index-headers.html | 0001345099-26-000045 |
| Document: 0001345099-26-000045-index.html | 0001345099-26-000045 |
| Document: 0001345099-26-000045.txt | 0001345099-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
6-K
| $1.70 awaiting T+20 | awaiting T+20 | — | $1.55 (−8.82%) |
|
Apr 30, 2026
6w ago
|
6-K
| $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.55 (−8.82%) |
|
Apr 17, 2026
8w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.55 (−3.13%) |
|
Apr 15, 2026
8w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access